Atrium Health Levine Cancer Institute | Strategic Alliance Partners

Latest from Atrium Health Levine Cancer Institute

Dr. Puechl on Choosing Between PARP Inhibitors in Ovarian Cancer

January 11, 2021

Video

Allison M. Puechl, MD, discusses choosing between PARP inhibitors in ovarian cancer.

Dr. Crane on the Benefit of Maintenance PARP Inhibitors in Ovarian Cancer

January 08, 2021

Video

Erin K. Crane, MD, MPH, discusses the benefit of maintenance PARP inhibitors in ovarian cancer.

Dr. Brown on the Utility of Minimally Invasive Surgery in Ovarian Cancer

January 08, 2021

Video

Jubilee Brown, MD, discusses the utility of minimally invasive surgery in ovarian cancer.

Immunotherapy Combos Take Next Step in Gynecologic Cancers

December 29, 2020

Article

R. Wendel Naumann, MD, discusses numerous investigations of PD-1 inhibitors in combination with PARP inhibitors or other targeted agents, as well as chemotherapy, and how it could finally start the next chapter of immunotherapy in gynecologic malignancies.

Weighing Risks and Benefits Is Critical With Second-Line Maintenance PARP Inhibition in Ovarian Cancer

December 19, 2020

Article

Allison M. Puechl, MD, discusses the role of second-line maintenance therapy in patients with recurrent ovarian cancer and considerations that may limit the accessibility of PARP inhibitors in this space.

Dr. Ghosh on Unmet Needs With CAR T-Cell Therapy in DLBCL

December 01, 2020

Video

Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses unmet needs with CAR T-cell therapy in diffuse large B-cell lymphoma.